CNBX Pharmaceuticals Reports Dire Financials, Massive Dilution, and Going Concern Warning
CNBX has more than doubled off its 52-week low of $0 on light trading volume (0.1× avg).
Summary
CNBX Pharmaceuticals reported critically low cash, a significant increase in net loss, and continued massive share dilution, reinforcing substantial doubt about its ability to continue as a going concern.
Key Events · Earnings and Guidance · CNBX
-
Critically Low Cash Reserves
Cash and cash equivalents plummeted to $9,487 as of May 31, 2026, down from $15,111 in August 2025. The company projects minimum expenses of $1,000,000 over the next 12 months, indicating a severe liquidity crisis.
-
Substantial Doubt About Going Concern
Management reiterated substantial doubt about the company's ability to continue as a going concern, citing cumulative losses of $25.58 million and an inability to generate sufficient revenue or secure adequate financing.
-
Significant Net Loss Increase
The net loss for the nine months ended May 31, 2026, more than doubled to $311,982, compared to $163,867 for the same period last year, driven by increased operating expenses.
-
Massive Share Dilution Continues
The company issued 921,805,889 shares from convertible loan conversions for $148,561 during the nine-month period, and an additional 130,000,000 shares for $15,600 post-period. This represents a total of $164,161 in dilutive financing, equivalent to 67% of the current market capitalization.
Analysis · CNBX · Life Sciences
CNBX Pharmaceuticals continues to face severe financial distress, with critically low cash reserves of just $9,487 against projected expenses of $1,000,000 for the next year. The company's net loss more than doubled, and it continues to rely on highly dilutive financing, issuing shares equivalent to 67% of its current market capitalization from recent loan conversions. The reiterated 'going concern' warning underscores the company's precarious survival outlook.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 42.7% of the 288 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.53%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CNBX was trading at $0.00 on OTC in the Life Sciences sector, with a market capitalization of approximately $245.2K. The 52-week trading range was $0.00 to $0.01. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.